Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
- PMID: 35166374
- PMCID: PMC9303338
- DOI: 10.1111/apt.16816
Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
Abstract
Background: Some drugs for irritable bowel syndrome (IBS) have serious side effects.
Aims: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure.
Methods: We collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV-defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables.
Results: Participants would accept a median 2.0% (IQR 0.0%-9.0%) risk of death in return for a 98.0% (IQR 91.0%-100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom-specific anxiety (P < 0.001 for trend), and lower IBS-related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores.
Conclusion: Patients are willing to accept significant risks in return for cure of their IBS symptoms.
Keywords: death; irritable bowel syndrome; risk; standard gamble.
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply.Aliment Pharmacol Ther. 2022 May;55(9):1220-1221. doi: 10.1111/apt.16917. Aliment Pharmacol Ther. 2022. PMID: 35429032 No abstract available.
-
Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?Aliment Pharmacol Ther. 2022 May;55(9):1218-1219. doi: 10.1111/apt.16909. Aliment Pharmacol Ther. 2022. PMID: 35429038 No abstract available.
-
Reizdarm: Selbst potenziell letale Therapien wären willkommen.MMW Fortschr Med. 2022 Sep;164(16):26-27. doi: 10.1007/s15006-022-1825-8. MMW Fortschr Med. 2022. PMID: 36123469 German. No abstract available.
Similar articles
-
Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome.Neurogastroenterol Motil. 2023 Feb;35(2):e14483. doi: 10.1111/nmo.14483. Epub 2022 Sep 30. Neurogastroenterol Motil. 2023. PMID: 36178331 Free PMC article.
-
Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief.Clin Gastroenterol Hepatol. 2021 Jan;19(1):80-86. doi: 10.1016/j.cgh.2020.04.003. Epub 2020 Apr 11. Clin Gastroenterol Hepatol. 2021. PMID: 32289536
-
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2023 May;57(10):1083-1092. doi: 10.1111/apt.17465. Epub 2023 Mar 13. Aliment Pharmacol Ther. 2023. PMID: 36914979
-
Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria.Clin Nutr. 2023 May;42(5):800-809. doi: 10.1016/j.clnu.2023.03.019. Epub 2023 Mar 31. Clin Nutr. 2023. PMID: 37031468
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
Cited by
-
Treating disorders of brain-gut interaction with multidisciplinary integrated care. Moving towards a new standard of care.JGH Open. 2024 May 20;8(5):e13072. doi: 10.1002/jgh3.13072. eCollection 2024 May. JGH Open. 2024. PMID: 38770352 Free PMC article. Review.
-
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.Aliment Pharmacol Ther. 2022 Jul;56(1):110-120. doi: 10.1111/apt.16939. Epub 2022 May 1. Aliment Pharmacol Ther. 2022. PMID: 35491477 Free PMC article.
-
Impact of Rome IV irritable bowel syndrome on work and activities of daily living.Aliment Pharmacol Ther. 2022 Sep;56(5):844-856. doi: 10.1111/apt.17132. Epub 2022 Jul 6. Aliment Pharmacol Ther. 2022. PMID: 35794733 Free PMC article.
-
Patient satisfaction after remotely delivered gut-directed hypnotherapy for irritable bowel syndrome during the COVID-19 era: implications for future practice.BMJ Open Gastroenterol. 2022 Nov;9(1):e001039. doi: 10.1136/bmjgast-2022-001039. BMJ Open Gastroenterol. 2022. PMID: 36427905 Free PMC article.
-
The synthesis of the psychosocial and the physiological aspects of chronic digestive disease is at a crossroads.Transl Gastroenterol Hepatol. 2025 Jan 6;10:1. doi: 10.21037/tgh-24-102. eCollection 2025. Transl Gastroenterol Hepatol. 2025. PMID: 39944575 Free PMC article. No abstract available.
References
-
- Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2020;5:908‐917. - PubMed
-
- Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393‐1407. - PubMed
-
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1:133‐146. - PubMed
-
- Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10‐yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2007;103:1229‐1239. - PubMed
-
- Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital‐based, case‐control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38:1031‐1038. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources